Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.65 |
| ▸ | AKT2 | P31751 | 20/20 | 0.65 |
| ▸ | AKT3 | Q9Y243 | 20/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.57 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15974306 | 1.00 | AKT1 (0.65) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2554983 | 0.96 | AKT1 (0.60) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2554651 | 0.94 | AKT1 (0.58) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2549742 | 0.92 | AKT1 (0.65) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2557858 | 0.92 | AKT1 (0.65) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2555653 | 0.92 | AKT1 (0.56) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2551724 | 0.91 | AKT1 (0.66) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2552146 | 0.89 | AKT1 (0.62) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2554841 | 0.89 | AKT1 (0.62) | AKT1AKT2AKT3PIK3CAPRKG1 | |
| SCHEMBL2556504 | 0.89 | AKT1 (0.62) | AKT1AKT2AKT3PIK3CAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-06-21 | — | — | US | disclosed |
| EP-2694959-A2 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | Genentech, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2558864-A1 | FOX03A AS PREDICTIVE BIOMARKER FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | Genentech, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2012135749-A2 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | GENENTECH, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2011130654-A1 | FOX03A AS PREDICTIVE BIOMARKER FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | GENENTECH, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT1 1/4885AKT2 2/4885AKT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.